Kentera (previously Oxybutynin Nicobrand) (oxybutynin)
- Region
- 🇪🇺 EU
- Active substance
- oxybutynin
- Company
- Teva B.V.
- Status
- Authorised
- Therapeutic area
- Urinary Incontinence, Urge
- EU approval
- Tue 15 Jun 2004
- Application
- EMEA/H/C/000532
- ATC
- G04BD04
- Official record
- www.ema.europa.eu
Indication
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.
Regulatory milestones
No milestones recorded in the last year.
Follow Kentera (previously Oxybutynin Nicobrand)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.